NEAR SOLA BRIDGE,
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India.
Intas' success and incessant growth lies in clinical execution of successful and strategic moves made in the areas of manufacturing, R&D, Biotechnology and global operations over three decades. As on 31st of March 2018, Intas has recorded a global turnover of $1.7 billion at >20% CAGR over the last 5 years. Intas is currently ranked 11th in the Indian Pharma Market with 2.9% market share*.
In the domestic market, Intas enjoys leadership position in chronic therapies such as Neurology, Psychiatry, Cardiovasculars, Diabetes, Oncology, Urology, Nephrology, Rheumatology & Gynecology, Infertility, Gastroenterology, Pain Management and healthy presence in other major therapeutic segments.
Besides well-established domestic prominence, Intas is also present in more than 80 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Africa, Australia, New Zealand, Asia-Pacific as well as CIS and MENA countries. Intas' global strategy includes alliances with leading Global Pharma Companies for development and distribution of products as well as direct product distribution. The company is known for its range of products in Oncology and other hospital based therapeutic segments in the EU and US. After the landmark acquisition of Teva's assets, Intas has become a leading player in the generics market in the UK.
Intas has made a substantial commitment to its Biologics Business Unit in terms of creating R&D, manufacturing and marketing capabilities for its biotech portfolio. It is the first company to launch a biosimilar in EU (Filgrastim & Peg-filgrastim) as well as the first company to launch patented aqualip technology based delivery system in India.
Intas is one of the fastest growing Indian company in the biosimilar space with 13 commercialized biosimilars including Docetaxel & Paclitaxel. As on date, Intas continues its R&D efforts in chronic disease areas such as oncology (cancer), rheumatology, auto-immune, nephrology, ophthalmology and plasma derived product based therapies.
Intas' success and growth is a direct influence of Intas' extensive R&D capabilities, its manufacturing abilities and its people. Every year, the company invests around 6-7% of its revenues in R&D. Besides building the regular portfolio of generic products, Intas' R&D is also focused on creating a pipeline of novel drug delivery technology based products and biologics and has invested over $125 million to develop and enhance its biosimilar capabilities over the past 8 years.
Intas operates fourteen formulation manufacturing facilities, of which seven are located in India, and the rest in the U.K. and Mexico. Two of their flagship facilities are accredited by top global regulators such as USFDA, EMA, MHRA, TGA, etc. It is also the first company in India to have its biologics manufacturing facility accredited by the European Health Authority.